reflect the distribution of functioning Kupffer cells and we must therefore discard the concept that focal scan defects represent "space-occupying lesions." The point to be stressed is that abscesses have more than one phase (as do necrotic tumors) and the actual size of the cavities (necrotic centra) can probably be more accurately assessed with ^{67}Ga-citrate than with ^{99m}Tc-sulfur colloid. This was demonstrated in both our cases by the discrepancy in size of the abscesses as seen on the ^{99m}Tc-sulfur colloid scans (larger) compared with the ^{67}Ga-citrate scans (smaller). Moreover, the rim of increased activity on the ^{67}Ga-citrate liver scans was essentially contained within the area of the ^{99m}Tc-sulfur colloid scan defects. The rationale for the larger scan defect with ^{99m}Tc-sulfur colloid is that the peripheral area of hyperemia about the acute abscess cavity inactivates the Kupffer cells in this region and, thus, the radiocolloid scan defect not only represents the abscess cavity but the inflammatory hyperemic zone. Delineation of the cavity is best done with ^{67}Ga-citrate since it localizes in the hyperemic zone and to only a lesser extent in the necrotic center. Secondly, as the abscess becomes older, the zone of hyperemia disappears and the phagocytic activity in this zone returns. This results in a defect on the ^{99m}Tc-sulfur colloid scan which is smaller and represents the negative defect of the pus cavity. This rapid return of phagocytic activity when the zone of hyperemia disappears may account for the discrepancy in the literature on the rate of healing of amebic abscesses.

We thank Maze and Wood for allowing us to reaffirm our observations.

GEORGE E. GESLIEN
Silas B. Hays Army Hospital
Fort Ord, California

REFERENCES

1. BLAIR DC, CARROLL M, CARR EA, et al: ^{67}Ga-citrate for scanning experimental staphylococcal abscess. *J Nucl Med* 14: 99–102, 1973

2. HARVEY WC, SILVA J, HAINES RS: Detection and delineation of abdominal abscesses in rabbits with ^{67}Ga. *Radiology* 107: 681–682, 1973

3. BURLESON RL, JOHNSON MC, HEAD H: Scintigraphic demonstration of experimental abscesses with ^{67}Ga citrate and ^{67}Ga labeled blood leukocytes. *Ann Surg* 78: 446–452, 1973

4. GUNASEKERA SW, KING LJ, LAVENDER PJ: The behavior of tracer gallium-67 towards serum proteins. *Clin Chim Acta* 39: 401–406, 1972

5. GESLIEN GE, THRALL JH, JOHNSON MC: Gallium scanning in acute hepatic amebic abscess. *J Nucl Med* 15: 561–563, 1973

TOXICITY OF ^{99m}Tc-Sn-EHDP

Tofe and Francis (*1*) representing Procter and Gamble state that the appropriate amount of ^{99m}Tc-Sn-EHDP for human administration (1–2 mg EHDP) for the purpose of skeletal scintigraphy is very low. The same authors state that 10–20 mg/kg/day EHDP has been therapeutically administered orally to patients with disordered mineral metabolism with no adverse effect. These statements are misleading.

An oral dose of 10–20 mg/kg/day of EHDP of which an average of 2–3% is absorbed (range, 0.1–15%) represents an average total absorbed dose of 14–42 mg (range, 0.7–210 mg) in a man weighing 70 kg (*2*). This dosage produces therapeutic effects in certain bone diseases (*2*), and reproducibly causes hyperphosphatemia(*2*) and decreased ionized serum calcium associated with elevation of plasma PTH (*3*). I would hesitate to claim that these effects may not be "adverse."

Obviously all EHDP injected intravenously is absorbed and the dose recommended by Tofe and Francis for bone scans, 1–2 mg, is definitely in the range of absorbed dose (> 0.7 mg) associated with the previously mentioned effects, at least in chronic administration of the drug to some patients.

Although the safety margin of the recommended bone scan dose of EHDP is acceptable, it most certainly is not a tracer dose and its having some pharmacologic action in at least a fraction of patients to whom it is administered can be predicted.

ROBERT S. HATTNER
University of California
San Francisco, California

THE AUTHORS' REPLY

We believe that the concern expressed about the possibility of a pharmacologic action related to the intravenous administration of ^{99}Tc-Sn-EHDP (1–2 mg EHDP) can be satisfied by the results of more extensive urinary excretion studies (unpublished) and a review of the recent literature.

Urinary excretion data collected on both normal patients and those with Paget's disease show that the